Clinical development of immunotherapies for HER2 + breast cancer: a review of HER2-directed monoclonal antibodies and beyond.

MLA

Costa, Ricardo L. B., and Brian J. Czerniecki. “Clinical Development of Immunotherapies for HER2 + Breast Cancer: A Review of HER2-Directed Monoclonal Antibodies and Beyond.” NPJ Breast Cancer, vol. 6, Mar. 2020, p. 10. EBSCOhost, https://doi.org/10.1038/s41523-020-0153-3.

APA

Costa, R. L. B., & Czerniecki, B. J. (2020). Clinical development of immunotherapies for HER2 + breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer, 6, 10. https://doi.org/10.1038/s41523-020-0153-3

Chicago

Costa, Ricardo L B, and Brian J Czerniecki. 2020. “Clinical Development of Immunotherapies for HER2 + Breast Cancer: A Review of HER2-Directed Monoclonal Antibodies and Beyond.” NPJ Breast Cancer 6 (March): 10. doi:10.1038/s41523-020-0153-3.